Palmar–plantar erythrodysesthesia due to docetaxel–capecitabine therapy is treated with vitamin E without dose reduction

Kara, İsmail Oğuz; Şahin, Berksoy; Erkisi, Melek

doi:10.1016/j.breast.2005.07.007

Cited by 49 publications

(45 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other therapies with benefit in case series include topical henna [112], keratolytics such as urea 12.5% [113], oral vitamin E 300 mg daily [114], topical dimethyl sulfoxide [72], and the cytoprotective agent amifostine at intravenous doses of 500 mg [115]. Anecdotal evidence suggests benefit in lifestyle modification, such as avoiding high temperatures, excessive exercise, or ill-fitting clothes and shoes [71,116,117].…”

Section: Managementmentioning

confidence: 99%

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Lipworth¹,

2009

View full text Add to dashboard Cite

Hand-foot syndrome (HFS), also called hand-foot skin reaction, palmar-plantar erythrodysesthesia, acral erythema, and Burgdorf reaction, is a dose-limiting cutaneous toxicity of many chemotherapeutic agents. Recently, the multiple tyrosine kinase inhibitor class of novel targeted therapies, including sorafenib and sunitinib, has emerged as an important cause of HFS, with 10–28% of patients treated with sunitinib and 10–62% of patients treated with sorafenib reporting HFS. This review examines the epidemiology, clinical features, histopathology, pathogenesis models, prognostic implications, and management of HFS, with particular attention to HFS induced by sorafenib and sunitinib. The high prevalence of HFS reported by patients treated with these medications underscores the need for greater understanding of the pathogenesis and management of this syndrome.

show abstract

Section: Managementmentioning

confidence: 99%

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Lipworth¹,

2009

View full text Add to dashboard Cite

show abstract

“…Therefore, a combined prevention strategy is recommended consisting of adequate behavioral measures and application of an antioxidant-containing cream providing a high RPF during the entire period of chemotherapeutic treatment. The efficiency of oral or topical antioxidant substances in the treatment of PPE has been shown in previous studies [3,21,23,24] favoring the assumption of a pathomechanism based on the topical formation of free radicals in the skin after excretion of the chemotherapeutic agent [18,19]. The high RPF and the continuous topical application of ointment enhance the antioxidant efficiency at the site of application.…”

Section: Resultsmentioning

confidence: 97%

Influence of Mechanical Stress on Palmoplantar Erythrodysesthesia - a Case Report

Jung

Sehouli²,

Patzelt³

et al. 2015

Oncol Res Treat

View full text Add to dashboard Cite

Background: Cutaneous adverse events can have an important negative influence on quality of life and compliance in affected patients. Palmoplantar erythrodysesthesia (PPE; hand-foot syndrome) is a cutaneous toxicity associated with chemotherapeutic treatment, which necessitates treatment interruption or dose reduction in severe cases. This case report of pegylated liposomal doxorubicin-induced PPE shows the influence of mechanical stress on the development of skin lesions in various locations and the importance of patient education and compliance. Case Report: We present the case of a 43-year-old female patient diagnosed with ovarian cancer and having undergone surgical and chemotherapeutic treatment. The development of extensive grade 3 PPE affecting numerous areas of the body particularly exposed to mechanical pressure necessitated dermatological treatment. The combination of local application of an antioxidant-containing ointment and the patient's compliance made it possible to continue chemotherapy without interruption or dose reduction. Conclusion: The development of PPE often limits the use of chemotherapeutic agents, and this case report can provide a possible therapeutic and preventive strategy for affected patients.

show abstract

“…Routine application of topical emollients such as petrolatum-lanolin-based ointments 26 and udder cream can be implemented in both the prevention and the treatment of HFS. 7,23 Some authors have found treatment with urea cream to be effective, 27 although the percentage of patients with moderate or severe HFS symptoms was not decreased by twice daily urea-lactic acid cream in a randomized, doubleblind, placebo-controlled phase 3 trial evaluating 137 patients who were receiving capecitabine. 37 Topical anesthetics and cold compresses can be useful for symptomatic control.…”

Section: Commentmentioning

confidence: 99%

“…37 Topical anesthetics and cold compresses can be useful for symptomatic control. 12,23 Treatment with systemic medications, including pyridoxine, [28][29][30][31][32][33] celecoxib, 34 vitamin E, 7 and nicotine patches, 35 may be tried alone or in conjunction with topical therapies (Table 3). Notably, a randomized, double-blind phase 3 study of 360 patients who were receiving capecitabine did not show any benefit from the use of pyridoxine (200 mg/d) in the prophylaxis or treatment of HFS.…”

Section: Commentmentioning

confidence: 99%

“…4,5 Although HFS has the potential to substantially affect quality of life, it is not recognized as a lifethreatening condition 6 and rarely leads to hospitalization. 7 We report a case of HFS that was complicated by pseudomonal superinfection resulting in bacterial sepsis and death and provide a review of the HFS literature focusing on the management of this condition. To our knowledge, this is the first reported case of fatal HFS.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Capecitabine-Induced Hand-Foot Syndrome Complicated by Pseudomonal Superinfection Resulting in Bacterial Sepsis and Death

Hoesly¹

2011

Arch Dermatol

View full text Add to dashboard Cite

Background: Hand-foot syndrome (HFS) is a relatively common dermatologic toxic reaction to certain anticancer therapies. Although not life-threatening, this complication can reduce patient quality of life. Dose modification of the inciting agent serves as the most effective management of HFS, although a variety of anecdotal reports suggest that other agents may also be efficacious. We present the first reported case of fatal HFS (to our knowledge) and provide a comprehensive review of this condition.Observations: A 61-year-old woman with metastatic breast cancer who was undergoing treatment with capecitabine developed erythema, fissuring, and erosions over both hands and feet, consistent with HFS. Pseudomonal superinfection leading to bacterial sepsis and death rapidly ensued.Conclusions: Although HFS is widely regarded as a nonlife-threatening toxic reaction to cancer treatment, our case demonstrates that infectious complications of this condition can prove fatal. Prevention, early recognition, and implementation of various management strategies for HFS and its infectious complications are important in optimizing patient quality of life and minimizing unfavorable outcomes.

show abstract

Palmar–plantar erythrodysesthesia due to docetaxel–capecitabine therapy is treated with vitamin E without dose reduction

Cited by 49 publications

References 42 publications

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Influence of Mechanical Stress on Palmoplantar Erythrodysesthesia - a Case Report

Capecitabine-Induced Hand-Foot Syndrome Complicated by Pseudomonal Superinfection Resulting in Bacterial Sepsis and Death

Contact Info

Product

Resources

About